Diagnosis of autoimmune disease
AssigneesDana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., The Trustees of the Leland Stanford Junior University, Department of Veterans Affairs
InventorsKevin C. O'Connor, David A. Hafler, Kai W. Wucherpfennig, Katherine McLaughlin, William H. Robinson, Lawrence Steinman
Life of this patent
Estimating the term…
Abstract
Methods and compositions for diagnosing and treating autoimmune disease, e.g., acute disseminated encephalomyelitis (ADEM), are described.
Claims15
A method of detecting the presence of autoantibodies to myelin oligodendrocyte glycoprotein (MOG) in a subject, the method comprising:
- obtaining a sample comprising serum or CSF from the subject;
- contacting the sample with a multimeric polypeptide, wherein the multimeric polypeptide comprises two or more fusion polypeptides comprising
- (i) a first portion comprising an antigenic extracellular domain of MOG comprising the sequence RISPGKNATGMEVGWYRS (SEQ ID NO:24);
- and
- (ii) a second portion comprising a multimerizing domain linked to the first portion, optionally via a linker,
- under conditions that allow binding of the multimeric polypeptide to antibodies present in the sample, if any, to thereby form multimeric polypeptide/antibody complexes;
- and
- detecting the presence of said multimeric polypeptide/antibody complexes in the sample, wherein the presence of multimeric polypeptide/antibody complexes in the sample indicates the presence of autoantibodies to MOG in the subject.
A method of detecting the presence of antibodies to myelin oligodendrocyte glycoprotein (MOG) in a sample, the method comprising:
- contacting the sample with a tetrameric polypeptide,
- wherein the tetrameric polypeptide comprises four fusion polypeptides comprising
- (i) a first portion comprising an antigenic extracellular domain of MOG comprising the sequence RISPGKNATGMEVGWYRS (SEQ ID NO:24);
- and
- (ii) a second portion comprising a multimerizing domain linked to the first portion, optionally via a linker,
- under conditions that allow binding of the tetrameric polypeptide to antibodies present in the sample, if any, to form tetrameric polypeptide/antibody complexes;
- and
- detecting the presence of tetrameric polypeptide/antibody complexes in the sample, thereby detecting the presence of the antibody in the sample.
A method of detecting the presence of autoantibodies to myelin oligodendrocyte glycoprotein (MOG) in a subject, the method comprising:
- obtaining a sample comprising serum or CSF from the subject;
- contacting the sample with a multimeric polypeptide, wherein the multimeric polypeptide comprises two or more fusion polypeptides comprising
- (i) a first portion comprising an antigenic extracellular domain of MOG comprising amino acids 27-146 of SEQ ID NO:2;
- and
- (ii) a second portion comprising a multimerizing domain linked to the first portion, optionally via a linker,
- under conditions that allow binding of the multimeric polypeptide to antibodies present in the sample, if any, to thereby form multimeric polypeptide/antibody complexes;
- and
- detecting the presence of said multimeric polypeptide/antibody complexes in the sample, wherein the presence of multimeric polypeptide/antibody complexes in the sample indicates the presence of autoantibodies to MOG in the subject.
A method of detecting the presence of antibodies to myelin oligodendrocyte glycoprotein (MOG) in a sample, the method comprising:
- contacting the sample with a tetrameric polypeptide,
- wherein the tetrameric polypeptide comprises four fusion polypeptides comprising
- (i) a first portion comprising an antigenic extracellular domain of MOG comprising amino acids 27-146 of SEQ ID NO:
- 2;
- and
- (ii) a second portion comprising a multimerizing domain linked to the first portion, optionally via a linker,
- under conditions that allow binding of the tetrameric polypeptide to antibodies present in the sample, if any, to form tetrameric polypeptide/antibody complexes;
- and
- detecting the presence of tetrameric polypeptide/antibody complexes in the sample,
- thereby detecting the presence of the antibody in the sample.
Dependencies are inferred from the claim text.